Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.

Breast cancer (Tokyo, Japan)·2026
Same author

RNA-seq Splicing Profile of the <i>CDH1</i> Gene and Its Impact on the Clinical Pathogenicity Classification of <i>CDH1</i> Variants: A Description of Alternative and Pathogenic Splicing Patterns.

Cancers·2025
Same author

Screening Mammography and Breast Cancer: Variation in Risk with Rare Deleterious or Predicted Deleterious Variants in DNA Repair Genes.

Cancers·2025
Same author

Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.

European journal of cancer (Oxford, England : 1990)·2023
Same author

Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.

European journal of cancer (Oxford, England : 1990)·2022
Same author

Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.

Clinical breast cancer·2022

Related Experiment Video

Updated: Apr 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.

Bruce Acres1, Gisele Lacoste2, Jean-Marc Limacher3

  • 1Bruce Acres Consulting, Strasbourg, France.

Current Topics in Microbiology and Immunology
|February 23, 2015
PubMed
Summary

Antigen-specific immunotherapy for cancer, particularly using the MUC1 antigen, explores various vaccine strategies. Understanding a patient's immune status is crucial for effective cancer treatment.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Antigen-specific immunotherapy offers a targeted approach to cancer treatment, distinct from traditional chemotherapy.
  • The MUC1 antigen is a key target for developing novel cancer immunotherapies.

Purpose of the Study:

  • To review and describe various MUC1-targeted antigen-specific immunotherapy strategies tested clinically.
  • To highlight the importance of assessing patient immune status before initiating immunotherapy.

Main Methods:

  • Review of clinical studies involving MUC1-based therapeutic vaccines.
  • Description of diverse vaccine platforms including monoclonal antibodies, polypeptides, dendritic cells, RNA, DNA, and viral vectors.

Main Results:

  • Multiple MUC1-targeting vaccine approaches have been investigated.
  • The development of MUC1-specific vaccines encompasses a range of biotechnological methods.

Conclusions:

  • Antigen-specific immunotherapy aims to empower the patient's immune system to eliminate cancer cells.
  • Pre-treatment immune profiling is essential for optimizing patient response to MUC1-targeted therapies.